. Author manuscript; available in PMC: 2014 Nov 1.

Published in final edited form as: Pharmacotherapy. 2013 Apr 18;33(11):1199–1213. doi: 10.1002/phar.1270

Table 9.

Reversal of Dabigatran and Rivaroxaban: A Crossover Randomized Controlled Trial

Eerenberg 2011⁸⁹ (RCT; crossover)
Number of patients	12
Disease	Healthy
Anticoagulant Drug	Dabigatran 150mg twice daily or Rivaroxaban 20mg twice daily
Coagulation assays measured after intervention	Yes
Length of drug therapy prior to intervention	2 1/2 days for each medication
Intervention	50 units of 4 Factor PCC/kg
Outcome	PCC immediately and completely reversed PT for rivaroxaban patients (p <0.001). PCC had no effect on aPTT, ECT, and TT for dabigatran.

RCT = randomized clinical trial; PCC = prothrombin complex concentrate; PT = prothrombin time; aPTT = activated; partial thromboplastin time; TT = thrombin clotting time; ECT = ecarin clotting time.